Good MorningEquity markets could be volatile on Thursday following NVIDIA's blowout earnings report. The bar was set high, and NVIDIA blew right past it, producing more than 120% YoY revenue growth and widening margin. The bigger news is that demand for its data center and networking products remains strong, leading to better-than-expected guidance. The problem is that as high as the bar was set, the market hoped for another blowout and moved lower on the news. In this environment, NVIDIA could remain range-bound for the foreseeable future.
Volatility could persist through the end of the week. The July read of the PCE price index is due on Friday ahead of a three-day weekend and is expected to accelerate. Accelerating inflation is contrary to the idea of falling interest rates and will be a negative for stocks. As it is, the market is banking on a rate cut in September and three by year's end, which may be too many too soon. Featured: SAGA Metals nears a key milestone in critical minerals race (Ad) 
|
Consumer Discretionary | |
MGM Resorts International (NYSE: MGM) shares have struggled to exit a trading range entered in 2021 and recently moved to retest the lows, providing an opportunity the insiders took advantage of. The low was triggered by fear of recession caused by weaker-than-expected labor market data, which is ... Read the Full Story |
|
From Our Partners | | Barrick Mining has spent decades building one of Nevada's richest gold districts, anchored by Fourmile, Goldrush, and Cortez Hills, deposits that could hold up to 60 million ounces of gold.
One overlooked explorer controls 142 claims bordering Fourmile and sitting less than a mile from Goldrush. New geological modeling aims to reveal what's beneath this largely untested ground, while a planned 5% royalty spin-off could give shareholders a separate stake in the project. | | Read the full report before the next catalyst hits |
|
Consumer Discretionary | |
When investors think of commodities and their long-term demand cycles, gold and silver often come to mind as investments that can take advantage of the market's long-term upside. However, the answer to aligning a portfolio with a long-term winning commodity involves figuring out which leading econ... Read the Full Story |
|
Communication Services | |
Earnings results from the Q2 reporting cycle are mixed. Some are good, and some are bad. The takeaway is that some are good, and the analysts reward those companies with upgrades and price target revisions to increase their share prices. That is the focus of this article: the three stocks the most... Read the Full Story |
|
From Our Partners | | Trader Chris Pulver says a new SEC document dropping the day-trading limit to $2,000 has created the biggest retail opportunity he has seen in over 30 years.
His strategy targets what he calls Flashpoints - moments when market makers must move billions of dollars on the S-P 500 in a narrow window. Research shows one recent signal would have returned 83.7% in 36 minutes and another 62.8% in 51 minutes.
Lance Ippolito flew to Utah for a full breakdown of the method. | | Tap here to see the complete Flashpoint trading breakdown now |
|
Consumer Discretionary | |
Kohl's Corporation (NYSE: KSS) finds itself navigating choppy waters in the turbulent sea of the retail sector. The renowned omnichannel retailer, known for its value-driven offerings and loyal customer base, recently released its second-quarter fiscal year 2024 earnings report. Kohl’s earni... Read the Full Story |
|
Consumer Discretionary | |
Chewy’s (NYSE: CHWY) stock price has struggled since the peaks set in 2020 because it could not sustain the wicked-hot growth pace driven by pandemic spending and stimulus measures. Today’s takeaway is that the market for Chewy stock has normalized, and its business turned a corner i... Read the Full Story |
|
From Our Partners | | Lance Ippolito spent nearly two decades trading the markets, appearing on MoneyShow, Cheddar TV, CNN Money, and MarketBeat.
His free guide, Options Trading Explained, covers two tickers pros call their secret weapon, Wall Street's daily hidden edge, and a strategy that targets payouts around 4 PM ET.
It also explains how to avoid overnight risk when trading options. | | Download your free options trading guide now |
|
Real Estate | |
Last Friday, Federal Reserve Chair Jerome Powell provided the most unambiguous indication yet that the central bank is preparing to lower historically high interest rates in September. While he didn't specify the exact amount of the rate cut, most experts anticipate a quarter-point reduction. Powe... Read the Full Story |
|
Technology | |
AI is big business, and Ambarella (NASDAQ: AMBA) will benefit from it over the next decade, probably longer. While attention has been fixed on infrastructure names like NVIDIA (NASDAQ: NVDA), Microsoft (NASDAQ: MSFT), and Oracle (NYSE: ORCL), the time has come to pay attention to the next wave of ... Read the Full Story |
|
Materials | |
Over an economic cycle, it is no secret that a few asset classes tend to outperform the rest under the right fundamental conditions, something that investors can get behind to get their capital on what could be the winning side of history. With business activity slowing down for 21 months, accordi... Read the Full Story |
|
Healthcare | |
During times of market volatility, it’s always good for long-term investors to take a breath and zoom out. That doesn’t mean getting out of the markets as fast as possible. Instead, it means looking back at the past performance of the stocks they own or those on their watchlist(s).
... Read the Full Story |
|
Markets | |
Investors might begin to question whether this surge has gone too far or too fast as the utilities sector continues its impressive climb. With the sector ETF's Utilities Select Sector SPDR (NYSE: XLU) recent outperformance, some might be wondering if it's now overbought and due for a pullback in... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington. | | View Today's Stock Pick |
|
